Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,139,340
  • Shares Outstanding, K 119,427
  • Annual Sales, $ 18,470 K
  • Annual Income, $ -589,530 K
  • EBIT $ -566 M
  • EBITDA $ -556 M
  • 60-Month Beta 0.59
  • Price/Sales 222.12
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 52.21% ( -6.94%)
  • Historical Volatility 34.43%
  • IV Percentile 14%
  • IV Rank 10.96%
  • IV High 110.92% on 04/09/25
  • IV Low 44.98% on 01/22/25
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,880
  • Volume Avg (30-Day) 1,460
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 101,551
  • Open Int (30-Day) 98,823

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.32
  • Number of Estimates 11
  • High Estimate -0.35
  • Low Estimate -1.60
  • Prior Year -1.31
  • Growth Rate Est. (year over year) -0.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.99 +4.28%
on 06/23/25
35.09 -4.93%
on 07/02/25
+1.06 (+3.28%)
since 06/06/25
3-Month
29.31 +13.82%
on 05/15/25
43.51 -23.33%
on 04/30/25
-2.63 (-7.31%)
since 04/07/25
52-Week
29.31 +13.82%
on 05/15/25
61.38 -45.65%
on 07/26/24
-22.15 (-39.90%)
since 07/05/24

Most Recent Stories

More News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTK : 33.36 (-3.75%)
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

CYTK : 33.36 (-3.75%)
Cytokinetics to Participate in the Jefferies Global Healthcare Conference

CYTK : 33.36 (-3.75%)
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

CYTK : 33.36 (-3.75%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTK : 33.36 (-3.75%)
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

CYTK : 33.36 (-3.75%)
Cytokinetics Announces Positive Topline Results From MAPLE-HCM

CYTK : 33.36 (-3.75%)
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

CYTK : 33.36 (-3.75%)
Cytokinetics to Hold Annual Meeting of Stockholders

CYTK : 33.36 (-3.75%)
Cytokinetics: Q1 Earnings Snapshot

Cytokinetics: Q1 Earnings Snapshot

CYTK : 33.36 (-3.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 35.76
2nd Resistance Point 35.17
1st Resistance Point 34.26
Last Price 33.36
1st Support Level 32.76
2nd Support Level 32.17
3rd Support Level 31.26

See More

52-Week High 61.38
Fibonacci 61.8% 49.13
Fibonacci 50% 45.35
Fibonacci 38.2% 41.56
Last Price 33.36
52-Week Low 29.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar